BCFC/iStock Editorial via Getty Images McKesson ( NYSE: MCK ) said it will acquire a controlling interest in Core Ventures for $2.49B in cash. Core Ventures was established by Florida Cancer Specialists & Research Institute (FCS).
MCK will hold 70% of the company, and after the closing of the deal, Core Ventures will become part of the Oncology platform, and financial results will be reported within McKesson’s U.S. Pharmaceutical segment.
FCS will retain a minority interest in Core Ventures. More on McKesson McKesson Corporation (MCK) Q1 2025 Earnings Call Transcript McKesson Corporation: An Interesting Health Giant With A Hidden Gem McKesson in talks to acquire Florida cancer chain - Bloomberg.
